ImmunityBio Receives UAE Marketing Authorization for ANKTIVA
CULVER CITY, Calif., July 29, 2026 ImmunityBio announced that the Emirates Drug Establishment (EDE) has granted Marketing Authorization for...
ImmunityBio
Advertisement
ImmunityBio Highlights ANKTIVA Data in Lung and Bladder Cancer at ASCO 2026
CULVER CITY, Calif., June 1, 2026 ImmunityBio announced new clinical and comparative data from its ANKTIVA® (nogapendekin alfa inbakicept-pmln)...
ImmunityBio’s ANKTIVA Expansion Review Accepted by FDA
CULVER CITY, Calif., May 19, 2026 ImmunityBio announced that the U.S. Food and Drug Administration (FDA) has accepted its...
ImmunityBio to Present ANKTIVA Data at AUA 2026
CULVER CITY, Calif. – May 5, 2026 ImmunityBio Inc. has announced it will present new comparative clinical data and...
Advertisement
